Friday, August 29, 2025
  • Home
  • About us
  • Privacy policy
  • Advertise with us
  • Contact us
Fii News Logo
No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
Newsletter
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports
Fiinews
No Result
View All Result
Home Markets

Market: India-US partnership for AI-enable discovery

Fiinews by Fiinews
July 31, 2025
in Markets
Reading Time: 2 mins read
A A
0
Alphameld
0
SHARES
16
VIEWS
LinkedinShare on Twitter

0:00

VedTechBio-AlphaMeld to do preclinical proof-of-concept

Bengaluru’s VedTechBio Research Pvt Ltd has formed a partnership with AlphaMeld Corporation, a US-based leader in real-world applications of generative AI for drug discovery and development, covering preclinical discovery through human proof-of-concept.

“With VedTechBio, we’re pairing AI-enabled drug discovery with real-world execution,” Dr Krishnan Nandabalan, Chairman & CEO of AlphaMeld said on 31 July.  “This collaboration bridges cutting-edge AI-driven discovery with translational readiness for scalable drug discovery success https://fieo.org/.”

Momentum and Market Impact

VedTechBio’s demonstrated ability to compress key discovery phases positions the company to capture significant value in the rapidly expanding global AI drug discovery market. The company and its partners are currently in active discussions with major pharmaceutical companies in the US and EU regarding collaborations arising from the RxAgentAI platform http://who.int.

“We’re seeing unprecedented interest from pharmaceutical partners who recognize that our platform delivers drug candidates in an acceptable cost and timeframe, giving us a competitive advantage in bringing life-saving therapies to patients,” said Sudhir Nagarajan, Founder and Managing Director, VedTechBio http://main.mohfw.gov.in. 

VedTechBio, which delivers AI-enabled end-to-end solutions in drug discovery and development, has also announced enhancements to its RxAgentAI™ platform, cutting drug discovery timelines in half alongside a strategic with AlphaMeld Corporation to co-develop multiple therapies for metabolic and rare diseases.

RxAgentAI is an autonomous, multi-agentic intelligence system augmented by deep, domain-specific knowledge. It redefines research workflows, orchestrating complex tasks from precise target identification to intricate drug design and testing.

RxAgentAI’s unique expert-in-the-loop mode seamlessly integrates human expertise with agent outputs.

This ensures unparalleled accuracy, transparency, and scientific rigour, resulting in impacts exemplified by:

•  30% reduction in target and drug identification timelines

•  50% compression of full target–disease–drug analysis workflows

•  Rare disease landscape mapping shortened from 12 weeks to under 3

“We’re building a future where AI proactively advances discovery,” said Nagarajan. “RxAgentAI marks a fundamental shift from passive tools to collaborative intelligence, purpose-built for translational impact.” Fiinews.com

Tags: VedTechBio
ShareTweetShare

Related Posts

Flipkart
Markets

Market: Flipkart expands supply chain

by Fiinews
August 29, 2025
0
11

Badri creates a hybrid network across Bharat Flipkart, India’s homegrown e-commerce marketplace, is expanding its pan-India supply chain infrastructure ahead...

Interglobe Enterprises
Markets

Market: Miiro opens on 1 Dec in Vienna

by Fiinews
August 29, 2025
0
15

Gupta has opened five hotels in just 16 months Miiro, the new lifestyle boutique hotel brand from InterGlobe Enterprises, has...

Albertsons

Market: Gopinath to develop Bengaluru Centre

August 28, 2025
11
ASSOCHAM

Market: SMEs face shifting demand patterns

August 26, 2025
11
MNRE

Market: India-Japan expands energy cooperation

August 26, 2025
18
Aabs 2025

Market: Hyderabad to host 100+ African-Asian academics

August 26, 2025
15
SBI YONO

POPULAR NEWS

  • Cristina Dnv

    Projects: Indian yards set to build green ships, says DNV expert

    0 shares
    Share 0 Tweet 0
  • Market: Indian-origin UGF scales heritage consumer brands globally

    0 shares
    Share 0 Tweet 0
  • Technologies: Royal Diamond sponsors aerspace Industries’ drones in UAE

    0 shares
    Share 0 Tweet 0
  • Investments: Foreign investors see India as long-term destination for fund placings

    0 shares
    Share 0 Tweet 0
  • Markets: Blue Dart maintains positive outlook on India

    0 shares
    Share 0 Tweet 0

Fiinews.com features through news articles on business opportunities in the Indian market for the benefits of foreigners. It is also a platform for international businesses to showcase through elaborate articles on their products & services to the Indian consumers and corporations exploiting industrialisation of the country.

7Clicks Media is a Singapore based Media & PR company offering over 100,000
impressions via our targeted communication strategy.

It is led by editor-in-chief Gurdip Singh who has worked over 45 years reporting on
Asian businesses.

Recent News

  • Manufacturing: BVK to scale GKD operations
  • Tech: Enterprises stuck in AI experimentation
  • Manufacturing: CG Semi launches first OSAT
  • Market: Flipkart expands supply chain
  • Project: A91 supports SASMOS global expansion

Pages

  • About US
  • ADVERTISE ON FIINEWS.COM
  • CONTACT US
  • EVENTS
  • FII-NEWS.COM PDF ARCHIVE
  • Home
  • News
  • PRIVACY POLICY

Subscribe to Newsletter

  • About
  • Advertise
  • Careers
  • Contact us

© 2024 FIINEWS - Design and developed by 7clicksmedia.

No Result
View All Result
  • Tenders
  • Projects
  • Markets
  • Manufacturing
  • Investment
  • Technology
  • Exports

© 2024 FIINEWS - Design and developed by 7clicksmedia.